Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia

In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of BCR-ABL1 mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range of targets may overcome resistance. CDDO-Me (bardoxolone...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Karoline V. Gleixner, Mathias Schneeweiss, Gregor Eisenwort, Daniela Berger, Harald Herrmann, Katharina Blatt, Georg Greiner, Konstantin Byrgazov, Gregor Hoermann, Marina Konopleva, Islam Waliul, Abbarna A. Cumaraswamy, Patrick T. Gunning, Hiroshi Maeda, Richard Moriggl, Michael Deininger, Thomas Lion, Michael Andreeff, Peter Valent
Format:	Artigo
Jezik:	Inglês
Izdano:	Ferrata Storti Foundation 2017-09-01
Serija:	Haematologica
Online dostop:	https://haematologica.org/article/view/8187
Oznake:	Označite Brez oznak, prvi označite!